Evidence map›Paper›PMID 37964352›Full record

ArticleHuman genomics2023

Identification of genetic loci jointly influencing COVID-19 and coronary heart diseases.

Siyue Wang, Hexiang Peng, Feng Chen, Chunfang Liu, Qiwen Zheng, Mengying Wang, Jiating Wang, Huan Yu, Enci Xue, Xi Chen and 9 more

Open access · goldAbstract read
In one paragraph

Article in Human genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Siyue WangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Hexiang PengDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Feng ChenDepartment of Intensive Care Unit, PLA Rocket Force Characteristic Medical Center, Beijing, 100088, China.
Chunfang LiuSchool of Public Health, Baotou Medical College, Baotou, 014040, China.
Qiwen ZhengCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101, China.
Mengying WangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Jiating WangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Huan YuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Enci XueDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Xi ChenDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Xueheng WangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Meng FanDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Xueying QinDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Yiqun WuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Jin LiDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Ying YeDepartment of Local Diseases Control and Prevention, Fujian Provincial Center for Disease Control and Prevention, Fuzhou, 350001, China.
Dafang ChenDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Yonghua HuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China. yhhu@bjmu.edu.cn.
Tao WuDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China. twu@bjmu.edu.cn.
Peking University · CNBaotou Medical College · CNBeijing Institute of Genomics · CNChinese PLA General Hospital · CNGansu Provincial Center for Disease Control and Prevention · CN

Funding

China Postdoctoral Science Foundation No. BX2021021Fujian Provincial Health Technology Project No. 2020CXB009Key Project of Natural Science Funds of China No. 8123066National Natural Science Foundation of China No. 81872695Natural Science Foundation of Fujian Province, China No. 2021J01352Special Fund for Health Scientific Research in Public Welfare No. 201502006
6 · The paper itself

Abstract

backgroundComorbidities of coronavirus disease 2019 (COVID-19)/coronary heart disease (CHD) pose great threats to disease outcomes, yet little is known about their shared pathology. The study aimed to examine whether comorbidities of COVID-19/CHD involved shared genetic pathology, as well as to clarify the shared genetic variants predisposing risks common to COVID-19 severity and CHD risks.

methodsBy leveraging publicly available summary statistics, we assessed the genetically determined causality between COVID-19 and CHD with bidirectional Mendelian randomization. To further quantify the causality contributed by shared genetic variants, we interrogated their genetic correlation with the linkage disequilibrium score regression method. Bayesian colocalization analysis coupled with conditional/conjunctional false discovery rate analysis was applied to decipher the shared causal single nucleotide polymorphisms (SNPs).

findingsBriefly, we observed that the incident CHD risks post COVID-19 infection were partially determined by shared genetic variants. The shared genetic variants contributed to the causality at a proportion of 0.18 (95% CI 0.18-0.19) to 0.23 (95% CI 0.23-0.24). The SNP (rs10490770) located near LZTFL1 suggested direct causality (SNPs → COVID-19 → CHD), and SNPs in ABO (rs579459, rs495828), ILRUN(rs2744961), and CACFD1(rs4962153, rs3094379) may simultaneously influence COVID-19 severity and CHD risks.

interpretationFive SNPs located near LZTFL1 (rs10490770), ABO (rs579459, rs495828), ILRUN (rs2744961), and CACFD1 (rs4962153, rs3094379) may simultaneously influence their risks. The current study suggested that there may be shared mechanisms predisposing to both COVID-19 severity and CHD risks. Genetic predisposition to COVID-19 is a causal risk factor for CHD, supporting that reducing the COVID-19 infection risk or alleviating COVID-19 severity among those with specific genotypes might reduce their subsequent CHD adverse outcomes. Meanwhile, the shared genetic variants identified may be of clinical implications for identifying the target population who are more vulnerable to adverse CHD outcomes post COVID-19 and may also advance treatments of 'Long COVID-19.'

Indexed as

Coronary DiseaseCOVID-19Bayes TheoremGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansPolymorphism, Single NucleotidePost-Acute COVID-19 Syndrome

Identifiers

PMID37964352
PMCPMC10647050
OpenAlexW4388655548

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.